GSK Drug Shows Promise in Lung Cancer Fight

A new drug could change how doctors treat lung cancer. This drug is called risvutatug rezetecan. It comes from GSK, working with its partner Hansoh.

Recent studies show good results. People taking this drug lived for 18.5 months on average. This is a big deal for those fighting lung cancer. It means they get more time.

This new drug is an ADC. ADC stands for antibody-drug conjugate. It works by finding cancer cells and delivering medicine right to them. This way, it aims to harm fewer healthy cells.

GSK's drug now competes with medicines from companies like Amgen and Merck & Co. This new option gives patients more hope. It pushes science forward in the fight against a tough disease.

Source: FierceBiotech